Subscribe to this Blog
Elekta Word Cloud

Posts Tagged ‘Axesse’

Elekta is improving the availability of cancer care for Russian patients by delivering clinical solutions, services and training to a number of key hospitals and cancer centers throughout Russia.

Elekta has won seven out of ten tenders being part of the new Russian National Oncology Program. The program was initiated under the auspices of Prime Minister Vladimir Putin in early 2009 with the aim to improve prevention and early detection of cancer.

Currently, patients in Russia are diagnosed with cancer mostly at stages III and IV, negatively affecting the survival rate and with expensive medical and drug treatment required. The program is considered an important step by the Russian Government to increase the life span for the Russian people.

Tatyana Golikova

Tatyana Golikova

“By 2012, the situation must be changed so that identification and treatment of cancer patients will already happen at stages I and II of the disease”, said the Russian Minister of Health, Tatiana Golikova at the presentation of the program.

As part of the program, Elekta will deliver four Elekta Synergy®, two Precise Treatment System™ and one Elekta Axesse™ to hospitals and cancer centers throughout the country. Engineers and medical physicists from Elekta and its Russian distributor MSM-Medimpex will provide training for all medical staff as well as services.

In addition, two other key centers in Russia recently purchased two Elekta Axesse™ for their stereotactic program.

“We are proud to be a part of the expansion of cancer care in Russia, and in making the latest clinical treatment solutions available to more patients throughout the country”, says Olof Sandén, Executive Vice President for Elekta Europe, Africa, Latin America and Middle East.

Elekta is continuing to execute on its plan for geographical expansion in key emerging markets, where Russia is one of several geographical areas with a large unmet need for cancer care.

”We have created a new structure and strategies supporting our focus on emerging markets where a large number of patients can benefit from life-saving technologies at an affordable cost per patient”, says Mr. Sandén.

Wake Forest University Baptist Medical Center

Live Premiere: Cancer Treated with Radiation Therapy

James J. Urbanic, M.D., a radiation oncologist, and Carnell J. Hampton, Ph.D., a physicist at the Comprehensive Cancer Center at Wake Forest University Baptist Medical Center, will use the most advanced linear accelerator to treat lung cancer.

 

Elekta Axesse™ image guided linear accelerator offers highly-accurate targeting of tumors and lesions virtually anywhere in the body. Typically requiring only one to five treatments, it achieves excellent results in fewer treatments than required by standard radiotherapy.

“Axesse raises our technological and treatment capabilities to an even higher level,” said Urbanic, lead physician on the Axesse team. “We are able to deliver higher and more conformal doses of radiation to the target in fewer fractions than with conventional radiation therapy techniques.”

For patients, that means more convenience and a faster return to their daily activities.

The Axesse combines three-dimensional image guidance with highly conformal beam shaping and robotic 6D patient positioning to deliver fast, effective and accurate treatments.

“Even the slightest patient misalignment can impact the accuracy of a dose,” said Urbanic.

With Axesse, the unit’s built-in CT imaging can allow for targeting accuracy within just a couple of millimeters. This ability to precisely conform the dose to the size and shape of the target offers clinicians the confidence to treat targets more aggressively while avoiding healthy tissue and critical structures.

Radiation therapy with these techniques is a treatment modality for a wide range of cancers including lung, prostate, head and neck, esophageal, spinal cord, pancreatic, liver metastases, recurrent gynecologic cancers, bone metastasis and adrenal cancer.

click to View the Live Webcast

More at http://www.youtube.com/wearefightingcancer

Elekta Axesse™ – Sistema de gestión del tratamiento estereotáctico guiado por imágenes

Elekta ofrece la gama de soluciones de tratamientos estereotácticos más completa del mundo para terapias contra el cáncer y otras afecciones
cerebrales, medulares, así como en otras zonas del cuerpo. El diseño y prestaciones resultantes del sistema reflejan décadas de liderazgo e
innovación*.

Nuestros clientes en los sectores de neurocirugía y oncología radioterápica se enfrentan al problema constante de la rentabilidad de la adopción de los protocolos de tratamiento más avanzados dentro de las restricciones de los recursos disponibles. Elekta Axesse™ ha sido diseñado específicamente para contemplar esta situación y proporcionar la calidad más alta de tratamiento al máximo número de pacientes.

Elekta Axesse

Elekta Axesse

* Elekta desarrolló el campo de la radiocirugía estereotáctica intracraneal (el primer Leksell® Gamma Knife® se presentó en 1968); presentó la radioterapia corporal estereotáctica (Stereotactic Body Frame® presentado en 1991; y fue pionera en la radioterapia de intensidad modulada y la radioterapia guiada por imágenes, Elekta Synergy® en uso clínico desde 2003).

Live WebEx:
Cancer Treated with Radiation Therapy Elekta Axesse™ SBRT Linear Accelerator
When: June 23, 2009, 5:00 PM EDT
Where: Wake Forest University Baptist Medical Center

James J. Urbanic, M.D., a radiation oncologist, and Carnell J. Hampton, Ph.D., a physicist at the Comprehensive Cancer Center at Wake Forest University Baptist Medical Center, will use the most advanced linear accelerator to treat lung cancer.

The Elekta Axesse™ image guided linear accelerator offers highly-accurate targeting of tumors and lesions virtually anywhere in the body. Typically requiring only one to five treatments, it achieves excellent results in fewer treatments than required by standard radiotherapy.

“Axesse raises our technological and treatment capabilities to an even higher level,” said Urbanic, lead physician on the Axesse team. “We are able to deliver higher and more conformal doses of radiation to the target in fewer fractions than with conventional radiation therapy techniques.” For patients, that means more convenience and a faster return to their daily activities.

For Full Details, please follow this link Live WebEx: Cancer Treated with Radiation Therapy Elekta Axesse™ SBRT Linear Accelerator

Elekta Axesse

Elekta Axesse

For a reminder e-mail of this Free WebEx, please choose this link: Receive an Email or TXT Reminder

Local Control of Brain Mets

Recent studies estimate that 25 percent of all cancer patients – particularly patients with melanoma, lung cancer, or advanced breast cancer – will develop brain metastases and require whole brain therapy. While whole brain radiotherapy is a treatment option, it also subjects healthy brain tissue to radiation dosages that may have negative side affects or limit the amount of therapeutic dose that can be applied in the event of a re-occurrence. In addition, whole brain radiation requires an interruption in the chemotherapy treatments that are so important to maintaining tumor control.

Dr. Christopher M. Duma, Neurological Surgeon at Hoag Memorial Hospital Presbyterian in Newport Beach, California will discuss the use of Leksell Gamma Knife® Perfexion™ to treat multiple brain metastases in a single session. Gamma Knife® surgery always has been especially good at treating very small targets with little or no damage to healthy tissue; but Perfexion is able to treat several targets faster and more efficiently making it a viable option of patients with brain metastases. The result is a fast and effective treatment for brain metastases that is easier on the patient, reduces the damage to healthy tissue that may limit future treatment options, and allows for concomitant chemotherapy for optimum primary tumor control.

Stereotactic Radiosurgery of the Spine

While Gamma Knife® surgery was initially invented to treat inoperable cancers and disorders in the brain, now the kind of stereotactic treatment precision established by Elekta can be applied to extra-cranial tumors. Today, the latest advancements in image guidance and dynamic arc delivery pioneered by Elekta combined with Leksell-quality fixation options support Stereotactic Radiosurgery (SRS) and Stereotactic Radiation Therapy (SRT) anywhere in the body to deliver optimal dose to the tumor, while protecting vital organs like the spinal cord.

Dr. Peter C. Gerszten, Associate Professor of Neurological Surgery and Radiation Oncology at the University of Pittsburgh Medical Center and co-editor of Spine Radiosurgery, will discuss the use of Elekta Axesse™ to perform stereotactic radiosurgery for spine and paraspinal lesions. According to Dr. Gerszten, “Axesse is fully optimized for SRS and SRT and therefore well suited for spine radiosurgery, providing patients a fast, safe, and effective treatment alternative or as an adjunct to open surgical intervention.”

More than sixty years ago, Professor Lars Leksell developed a three-coordinate head frame and revolutionized the field of stereotaxy. Twenty years later he conceived of replacing the surgical precision of the neurosurgeon with precisely targeted radiation, and invented the field of stereotactic radiosurgery (SRS). Today, Leksell Gamma Knife® Perfexion™ is still the benchmark upon which all other SRS methods are measured; Perfexion equipped with Extend Program*™ is capable of treating cancers of the head and neck and lesions previously unsuitable for Gamma Knife surgery; And Elekta Axesse™ supports SRS and SRT anywhere in the body making it a versatile cross-over solution for neurosurgery and oncology .

According to President and CEO of Elekta North America, Joseph K. Jachinowski,

“Since its very foundation, Elekta has sought to develop technology that allowed practitioners to achieve specific clinical objectives. Today Elekta Neuroscience is still developing technology to address the most challenging cases in neurosurgery and oncology, creating new treatment possibilities that are redefining what we call, human care.”



*Extend requires 510(k) review and is not yet commercially available in the U.S.

Visit with Elekta tt the 2009 American Association of Neurological Surgeons (AANS) Annual Meeting, May 4-6 at the San Diego Convention Center,

    WHAT ARE NON-HODGKIN’S LYMPHOMAS?


Lymphoma is a general term for cancers that develop in the lymphatic system. They account for about 4 percent of all cases of cancer in this country.

The most common type of lymphoma is called Hodgkin’s disease. All other lymphomas are grouped together and are called non- Hodgkin’s lymphomas.

The lymphatic system is part of the body’s immune defense system. Its job is to help fight diseases and infection. The lymphatic system includes a network of thin tubes that branch, like blood vessels, into the tissues throughout the body. Lymphatic vessels carry lymph, a colorless, watery fluid that contains infection-fighting cells called lymphocytes. Along this network of vessels are groups of small, bean-shaped organs called lymph nodes that filter the lymph as it passes through the nodes. Clusters of lymph nodes are found in the underarm, groin, neck, and abdomen. Other parts of the lymphatic system are the spleen, thymus, tonsils, and bone marrow. Lymphatic tissue is also found in other parts of the body, including the stomach, intestines, and skin.

Like all types of cancer, lymphomas are diseases of the body’s cells. Healthy cells grow, divide, and replace themselves in an orderly manner. This process keeps the body in good repair.

In the non-Hodgkin’s lymphomas, cells in the lymphatic system grow abnormally. They divide too rapidly and grow without any order or control. Too much tissue is formed, and tumors begin to grow. The cancer cells can also spread to other organs.

    WHAT ARE SYMPTOMS OF NON-HODGKIN’S LYMPHOMAS?


The most common symptom of non-Hodgkin’s lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Other symptoms may include fevers, night sweats, tiredness, weight loss, itching, and reddened patches on the skin. Sometimes there is nausea, vomiting, or abdominal pain . As lymphomas progress, the body is less able to fight infection.

These symptoms are not sure signs of cancer, however. They may also be caused by many common illnesses, such as the flu or other infections. However, it is important to see a doctor if any of these symptoms lasts longer than 2 weeks. Any illness should be diagnosed and treated as early as possible.

    HOW ARE NON-HODGKIN’S LYMPHOMAS DIAGNOSED?


The doctor asks about the patient’s medical history and performs a thorough physical exam. The only sure way to tell whether cancer is present is with a biopsy. Tissue from an enlarged lymph node is removed. By examining this tissue under a microscope, a pathologist can identify the cancer cells and tell whether the lymphoma is the kind that usually grows slowly or rapidly.

There are at least 10 types of non-Hodgkin’s lymphomas. Often, they are grouped by how fast they grow: low grade (slow growing), intermediate grade, and high grade (rapidly growing).

When lymphoma is diagnosed, the doctor needs to know what kind it is and the stage, or extent, of the disease. This information is very important for planning treatment. The stage indicates where the disease has spread and how much tissue is affected.

The following are checked:

* The number and location of affected lymph nodes
* Whether the affected lymph nodes are above, below, or on both sides of the diaphragm (the thin muscle under the lungs and heart that separates the chest from the abdomen)
* Whether the disease has spread to the bone marrow or organs outside the lymphatic system, such as the liver

In staging, the doctor usually orders blood tests and x-rays of the chest, bones, liver, and spleen. Other special tests include additional biopsies of the lymph nodes, bone marrow, and other sites. Most patients have lymphangiograms, x-rays of the lymphatic system using a special dye to outline the lymph nodes and vessels. The doctor may also want the patient to have a CT (or CAT) scan. A CT scan is a series of x- rays put together by a computer to form pictures of various parts of the body. Ultrasonography may also be used. This test creates pictures of internal organs using echoes of high-frequency sound waves.

WHAT TREATMENT IS THERE FOR NON-HODGKIN’S LYMPHOMAS?

Treatment decisions for non-Hodgkin’s lymphomas are complex. Before starting treatment, the patient might want a second doctor to review the diagnosis and treatment plan. Often, patients are referred to doctors or medical centers that specialize in the different treatments of Hodgkin’s disease. Also, patients may want to talk with their doctor about taking part in a research study of new treatment methods.
Methods of Treatment

Treatment planning takes into account the type of lymphoma, the stage of the disease, whether it is likely to grow slowly or rapidly, and the general health and age of the patient. For low-grade lymphomas, which usually grow very slowly and cause few symptoms, the doctor may decide to wait until the disease shows signs of spreading before starting treatment. Treatment for intermediate or high-grade lymphomas usually involves chemotherapy, with or without radiation therapy. In addition, surgery may be needed to remove a large tumor.

Chemotherapy is the use of drugs to kill cancer cells. Chemotherapy for non-Hodgkin’s lymphomas usually is a combination of several drugs. Some drugs are given by mouth. Others are injected into a blood vessel or muscle. The drugs travel through the bloodstream to nearly every part of the body. Chemotherapy is usually given in cycles: a treatment period followed by a rest period, then another treatment period and so on.

Radiation therapy uses high-energy rays to damage cancer cells and stop their growth. Radiation therapy is generally given in the outpatient department of a hospital or clinic. Most often, patients receive radiation therapy 5 days a week for 5 to 6 weeks.

    WHAT ARE THE SIDE EFFECTS OF TREATMENT?


The methods used to treat lymphomas are very powerful.

That is why the treatment often causes side effects. Fortunately, most side effects are temporary.

The side effects of chemotherapy depend mainly on the drugs given and the individual response of the patient. Chemotherapy commonly affects rapidly growing cells, such as blood cells that fight infection and cells that line the digestive tract. As a result, patients can have side effects such as a lowered resistance to infection, loss of appetite, nausea and vomiting, and mouth sores. They can also lose their hair. These side effects usually end after chemotherapy is finished.

During radiation therapy, patients can notice a number of side effects. They can become unusually tired as the treatment continues. Resting as much as possible is important. Skin reactions (redness or dryness) in the area being treated are common. Patients should be gentle with the treated area of skin. Lotions and creams should not be used without the doctor’s advice. When the chest and neck area is treated, patients may have a dry, sore throat and can have some trouble swallowing. Sometimes, they have shortness of breath or a dry cough. Radiation treatment to the lower abdomen can cause nausea, vomiting, or diarrhea . Some patients have tingling or numbness in their arms, legs, and lower back. These side effects gradually disappear when treatment is over.

Loss of appetite can be a problem for patients receiving chemotherapy or radiation therapy. Researchers are learning that patients who eat well are better able to tolerate the side effects of their treatment. Therefore, good nutrition is an important part of the treatment plan. Eating well means getting enough calories to prevent weight loss and having enough protein in the diet to build and repair skin, hair, muscles, and organs. Many patients find that eating several small meals and snacks throughout the day is easier than trying to have three large meals.

The side effects that patients have during cancer therapy vary from person to person and may even be different from one treatment to the next. Attempts are made to plan treatment to keep problems to a minimum. Doctors, nurses, and dietitians can explain the side effects of cancer treatment and can suggest ways to deal with them.

    WHAT HAPPENS AFTER TREATMENT FOR NON-HODGKIN’S LYMPHOMA?


Regular follow-up exams are very important for anyone who has been treated for non-Hodgkin’s lymphoma. Most relapses occur in the first 2 years after therapy.

Generally, checkups include a careful physical exam, x-rays, blood tests, and other laboratory tests. Patients should follow their doctor’s recommendations on health care and checkups. Having regular checkups allows problems to be detected and treated promptly should they arise.

When people have cancer, life can change for them and for the people who care about them. These changes in daily life can be difficult to handle. It is natural for a person with non-Hodgkin’s lymphoma to have many different and sometimes confusing emotions.

At times, patients and family members may be depressed, angry, or frightened. At other times, feelings may vary from hope to despair or from courage to fear. Patients usually are better able to cope with their emotions if they can talk openly about their illness and their feelings with family members and friends.

Concerns about the future, as well as about medical tests, treatments, a hospital stay, and medical bills, are common. Talking to doctors, nurses, or other members of the health care team may help to ease fear and confusion. Patients can take an active part in decisions about their medical care by asking questions about their treatment. Patients and family members often find it helpful to write down questions for the doctor as they think of them. Taking notes during visits to the doctor can help them remember what was said. They should ask the doctor to explain anything that is not clear.

Patients have many important questions to ask about their disease, and their doctor is the best person to provide answers. Most people want to learn what type of lymphoma they have, how the disease can be treated, and how successful the treatment is likely to be.

The patient’s doctor is the best person to give advice about working or to answer questions about other activities. Many patients find it also helps to talk with others who are facing similar problems. This kind of help is available through cancer-related support groups. A counselor or member of the clergy can offer additional emotional support.

    WHAT DOES THE FUTURE HOLD FOR PATIENTS WITH NON-HODGKIN’S LYMPHOMA?


More than 8 million Americans living today have had some type of cancer. Thirty years ago, few patients recovered from non-Hodgkin’s lymphoma. Because of advances in combination chemotherapy and radiation therapy, about half of all non-Hodgkin’s lymphoma patient now survive. As scientists find new and more effective treatments, the chances for recovery continue to improve.

Doctors often talk about “surviving” cancer, or they may use the word “remission” rather than “cure.” Even though many patients recover completely, doctors use these terms because non-Hodgkin’s lymphomas can recur. Patients are naturally concerned about their future and may try to use statistics they have read or heard about to try to figure out their own chances of being cured. It is important to remember, however, that statistics are averages based on the experiences of large numbers of people, and no two cancer patients are alike. Only the doctor who takes care of a patient knows enough about that person to discuss the prognosis.

Scientists at hospitals and medical centers all across the country are studying non-Hodgkin’s lymphomas. They are trying to learn more about the possible causes of the disease and how it might be prevented.

In addition, scientists are exploring new methods of treatment, including new drugs, drug combinations, and combinations of radiation therapy and chemotherapy. Other methods, such as bone marrow transplantation and biological therapy (also called immunotherapy), are also being studied in clinical trials. These trials are designed to answer scientific questions and to find out whether a promising new treatment is both safe and effective. Patients who take part in clinical trials make an important contribution to medical science and may have the first chance to benefit from improved treatment methods.

NON-HODGKIN’S LYMPHOMAS AT A GLANCE

    * A lymphoma is a cancer that develops in the lymphatic system
    * The most common symptom of non-Hodgkin’s lymphomas is a painless swelling in the lymph nodes in the neck, underarm or groin
    * Non-Hodgkin’s lymphomas are diagnosed with a biopsy of an enlarged lymph node
    * Treatment of non-Hodgkin’s lymphomas depends on the type and location of the lymphoma, as well as the age and health of the patient
    * Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy

Note:
This website is not intended as a substitute for professional medical advice and does not address specific treatments or conditions specific to any patient. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. The information on this website is subject to change.

Leading cancer centers in Moscow and Siberia to receive Russia’s most advanced stereotactic radiotherapy system.

Two of Russia’s leading research centers, The Meshalkin Research Institute of Circulation Pathology (NRIBCP, Novosibirsk, Russia) and the Hertzen Moscow Oncology Research Institute (MORI, Moscow, Russia), have purchased Elekta Axesse™ systems which will, for the first time in Russia, allow clinicians to treat cancer tumors throughout the body with ultra-high precision while minimizing damage to surrounding healthy tissue.

Elekta Axesse will help us to build the one of the most advanced cancer centers in Russia,” says Professor Alexander M. Karaskov, Director of the Meshalkin Research Institute. “The system combines speed and accuracy with the ability to target tumors throughout the body.”

Elekta Axesse will be delivered with the latest technology, Elekta VMAT (Volumetric Modulated Arc Therapy), which enables faster treatment time and more accurate targeting of the dose. Hertzen MORI will be the first clinic in Russia to provide this technology to patients.

“The system will enable us to attain very-high precision and accuracy for every patient, in many cases sub-millimeter. This is specifically important in treatment of difficult sites such as lung or liver,” commented Professor Anna Boyko from MORI. “The advanced 3D imaging capabilities of Elekta Axesse facilitate rapid, precise targeting of tumors, and the highly-conformal radiation delivery system effectively treats tumors while minimizing damage to a patient’s healthy tissue.”

This advanced technology is delivered with MOSAIQ®, the most advanced integrated suite of Electronic Medical Record (EMR) software in oncology; which enhances workflow, improves productivity and simplifies medical record accessibility throughout the department.

“Software support for efficient workflow is a key component in a treatment system and MOSAIQ, along with the entire software package supplied by Elekta, is second to none. In a clinical setting, the system manages documents, patient and user schedules and imports treatment plans into the EMR as well as verifies and records the treatment delivered, all handled from one integrated user environment. This definitely helps to streamline clinicians’ workflow, ultimately saving precious time,” says Dr. Olga Efimova, NRIBCP’s Head of Radiosurgery.

Generally, on the opinion of Professor Andrey Chernichenko, President of the Russian Association of the Therapeutic Radiation Oncologist (RATRO), “such sophisticated equipment will open new era for all Russian oncology – high precision, super effective irradiation for many ‘social important’ tumors.”

Elekta Axesse - world’s most complete portfolio of stereotactic treatment solutions for the treatment of cancer and diseases of the brain, spine and body

Elekta Axesse - world’s most complete portfolio of stereotactic treatment solutions for the treatment of cancer and diseases of the brain, spine and body.